For multiple sclerosis, the FDA has placed a clinical hold on Roche's BTK inhibitor fenebrutinib.

Published Date: 07 Dec 2023

The clinical hold relates to a safety concern that was noted in the phase 3 FENhance studies involving patients who had relapsing forms of multiple sclerosis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot